Abstract
Purpose
Low-dose, prolonged infusion of gemcitabine has effects similar to standard doses in several cancers. We evaluated the toxicity and efficacy of low-dose gemcitabine in prolonged infusion plus cisplatin in patients with advanced pleural mesothelioma.
Methods
Patients with mesothelioma received gemcitabine (250 mg/m2) in a 6-h infusion plus cisplatin (35 mg/m2) on days 1 and 8 every three weeks. We used the modified response evaluation criteria in solid tumours. This study is registered in clinical trials (NCT01869023).
Results
We included 39 patients; 82.1 % were low risk according to the European Organisation for Research and Treatment of Cancer prognostic group. Partial response was observed in 53.8 % (21/39), stable disease in 33.3 % (13/39) and progression in 12.8 % (5/39). The median progression-free survival was 6.9 months (95 % CI 3.2–10.6 months), and the associated factors were the EORTC risk and histology. The median overall survival was 20.7 months (95 % CI 10.7–30.8 months). The functional, physical and emotional roles and dyspnoea, insomnia and pain symptom scales improved. The most commonly graded 3/4 side effects were neutropenia (24.4 %), lymphopenia (14.6 %), thrombocytopenia (14.7 %) and anaemia (12.2 %).
Conclusions
Low-dose, prolonged gemcitabine infusion plus cisplatin has acceptable toxicity and high efficacy with improved quality of life, representing an affordable regimen for the low-income population.
Similar content being viewed by others
References
Selikoff IJ, Hammond EC, Seidman H (1980) Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46(12):2736–2740
Tsao AS, Wistuba I, Roth JA et al (2009) Malig Pleur Mesothelioma J Clin Oncol 27(12):2081–2090. doi:10.1200/JCO.2008.19.8523
Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89(10):716–724. doi:10.2471/BLT.11.086678 724A–724C
Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA et al (2010) Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241–251
García-López MP, Barrera-Rodríguez R (2000) Malignant mesothelioma: clinical and radiological description of 45 cases with and without asbestos exposure. Salud Publica Mex 42(6):511–519
Park EK, Takahashi K, Hoshuyama T et al (2011) Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 119(4):514–518. doi:10.1289/ehp.1002845
NCCN Guidelines for Treatment of Malignat Pleural Mesothelioma (2013) IOP National Comprehensive Cancer Network Web. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 23 Dec 2013
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644
van Meerbeeck JP, Gaafaar R, Manegold C et al (2005) Randomized phase III Study of Cisplatin With or Without Ralitrexed in Patients with Malignant Pleural Mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):2636–2644
Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73(3):256–263. doi:10.1016/j.lungcan.2011.04.014
Nowak AK, Byrne MJ, Williamson R et al (2002) A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87(5):491–496
Arrieta Ó, Medina LA, Estrada-Lobato E et al (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027–1032. doi:10.1038/bjc.2012.44
Ralli M, Tourkantonis I, Makrilia N et al (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441–3444
Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44–50. doi:10.1038/sj.bjc.6604421
Boons CC, VAN Tulder MW, Burgers JA et al (2013) The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer 33(9):3553–3561
Grossi F, Genova C, Gaitan ND et al (2013) Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer 81(2):236–240. doi:10.1016/j.lungcan.2013.03.021
Woods B, Paracha N, Scott DA et al (2012) Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 75(2):261–267. doi:10.1016/j.lungcan.2011.07.011
Zwitter M, Kovac V, Smrdel U et al (2009) Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 4(9):1148–1155. doi:10.1097/JTO.0b013e3181ae280f
Sezer O, Eucker J, Jakob C et al (2001) Achievement of complete remission in refractory Hodgkin’s disease with prolonged infusion of gemcitabine. Invest New Drugs 19(1):101–104
Brand R, Capadano M, Tempero M (2007) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15(4):331–341
Akrivakis K, Schmid P, Flath B et al (1999) Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 10(6):525–531
Cattel L, Airoldi M, Delprino L et al (2006) Pharmacokinetic evaluation of gemcitabine and 2′,2′-difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 17(Suppl 5):v142–v147
Maurel J, Zorrilla M, Puertolas T et al (2001) Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 12(9):713–717
Anderson H, Thatcher N, Walling J et al (1996) A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74(3):460–462
Pollera CF, Ceribelli A, Crecco M et al (1997) Prolonged infusion gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs 15(2):115–121
Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9(9):1003–1008
Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491–498
Plunkett W, Huang P, Xu YZ et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11):3–10
Edwards JG, Abrams KR, Leverment JN et al (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55(9):731–735
Fennell DA, Parmar A, Shamash J et al (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23(1):184–189
Arrieta Ó, Núñez-Valencia C, Reynoso-Erazo L et al (2012) Health-related quality of life in patients with lung cancer: validation of the Mexican–Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1):205–211. doi:10.1016/j.lungcan.2012.02.005
Schouwink JH, Kool LS, Rutgers EJ et al (2003) The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg 75(6):1715–1718
Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW et al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17(1):25–30
van Haarst JM, Baas P, Manegold Ch et al (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86(3):342–345
Kalmadi SR, Rankin C, Kraut MJ et al (2008) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60(2):259–263
Castagneto B, Zai S, Dongiovanni D et al (2005) Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 28(3):223–226
Favaretto AG, Aversa SM, Paccagnella A et al (2003) Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97(11):2791–2797
Ceribelli A, Gridelli C, De Marinis F et al (2003) Prolonged gemcitabine infusion in advanced non-small cell lung cancer carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98(2):337–343
de Perrot M, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413–1418. doi:10.1200/JCO.2008.17.5604
Lee CW, Murray N, Anderson H et al (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308–313. doi:10.1016/j.lungcan.2008.09.008
Kovac V, Zwitter M, Rajer M et al (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 23(2):230–238. doi:10.1097/CAD.0b013e32834d7a1c
Rea F, Marulli G, Bortolotti L et al (2007) Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 57(1):89–95
Bottomley A, Coens C, Efficace F et al (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25(36):5770–5776
Flores RM, Pass HI, Seshan VE et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626. doi:10.1016/j.jtcvs.2007.10.054
Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763–772. doi:10.1016/S1470-2045(11)70149-8
Acknowledgments
The study protocol was approved by the local Institutional Scientific and Bioethics Committee (INCAN/CC/458/01-INCAN/CB/516/01/CB/656) in accordance with the ethical standards laid down in the 1,964 Declaration of Helsinki and its later amendments and was registered in clinical trials (NCT01869023).
Conflict of interest
All patients signed written informed consent. The authors do not have any conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arrieta, O., López-Macías, D., Mendoza-García, VO. et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73, 975–982 (2014). https://doi.org/10.1007/s00280-014-2429-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-014-2429-5